Clinical studyOutcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease☆
References (21)
- et al.
Pregnancy outcome following cancer chemotherapy
Am J Med
(1980) Therapeutic abortions with a folic acid antagonist, 4-aminopteroglutamic acid (4-amino PGA) administered by the oral route
Am J Obstet Gynecol
(1952)- et al.
Methotrexate-induced congenital malformations
J Pediatr
(1968) Congenital malformation due to attempted abortion with aminopterin
Am J Obstet Gynecol
(1962)- et al.
Antirheumatic drug treatment during pregnancy and lactation
Scand J Rheumatol
(1985) - et al.
Effects of cancer chemotherapeutic agents on the human fetus
JAMA
(1960) Cytoxic drugs in pregnancy
Br J Obstet Gynaecol
(1968)Congenital anomalies among children born of mothers receiving chemotherapy for gestational trophoblastic neoplasma
Cancer
(1976)Early experiences with antimetabolites as abortifacient agents in man
Acta Endocrinol
(1956)- et al.
Twenty year experience of methotrexate (MTX) toxicity in rheumatoid arthritis
Arthritis Rheum
(1987)
There are more references available in the full text version of this article.
Cited by (216)
Offspring neurodevelopmental outcomes born to parents with chronic inflammatory arthritis using antirheumatic therapies: A scoping review
2023, Seminars in Arthritis and RheumatismManagement of Psoriasis During Preconception, Pregnancy, Postpartum, and Breastfeeding: A Consensus Statement
2021, Actas Dermo-SifiliograficasChemotherapy in pregnancy
2021, Clinical Pharmacology During PregnancyFetal methotrexate syndrome: A systematic review of case reports
2019, Reproductive ToxicologyCitation Excerpt :However, this was not possible as in most cases it could not be traced to which population the patient belonged. It is important to keep in mind that methotrexate does not always cause embryopathy [5,35,36] and that the exact risk of congenital malformations after in utero exposure to methotrexate is unclear. The variability in threshold of methotrexate teratogenicity might be explained by the combination of methotrexate dose, route of administration, timing and individual differences in sensitivity to methotrexate.
Special Issues in Pregnancy
2019, Abeloff’s Clinical OncologySpecial situations in inflammatory bowel disease: First Latin American consensus of the Pan American Crohn's and Colitis Organisation (PANCCO) (Second part)
2017, Revista de Gastroenterologia de Mexico
- ☆
This study was presented in part at the 51st Annual Meeting of the American Rheumatism Association, Washington, D.C., June 1987
Copyright © 1990 Published by Excerpta Medica Inc.